# Efficacy and Safety Study of Lucentis (Ranibizumab) and Visudyne (Verteporfin) Combination Therapy in Neovascular AMD

> **NCT00574093** · PHASE2 · COMPLETED · sponsor: **Fondazione G.B. Bietti, IRCCS** · enrollment: 15 (estimated)

## Conditions studied

- Neovascular Age Related Macular Degeneration

## Interventions

- **DRUG:** Ranibizumab; Verteporfin

## Key facts

- **NCT ID:** NCT00574093
- **Lead sponsor:** Fondazione G.B. Bietti, IRCCS
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-01
- **Primary completion:** 2009-06
- **Final completion:** 2009-10
- **Target enrollment:** 15 (ESTIMATED)
- **Last updated:** 2009-10-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00574093

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00574093, "Efficacy and Safety Study of Lucentis (Ranibizumab) and Visudyne (Verteporfin) Combination Therapy in Neovascular AMD". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT00574093. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*